FN2 Earnings Intelligence

ResMed Inc. analyst ratings

ResMed Inc. (RMD) analyst consensus, price targets, and firm-level rating history from FN2 Research.

Analyst Consensus ?

ConsensusHold34 ratings
Bullish1441.2%
Neutral1544.1%
Bearish514.7%

Analyst 52W Price Targets

$206.78Current
$175Low
$251.96Average
$345High

Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.

Firm-level rating actions

FMP grade actions identify the grading firm, not a named analyst.

FirmRatingPrior ratingActionDate
Mizuho Outperform OutperformMaintainJul 15, 2026
Citigroup Neutral BuyDowngradeJul 13, 2026
Jefferies Hold HoldMaintainJul 10, 2026
Wells Fargo Equal Weight Equal WeightMaintainJul 8, 2026
RBC Capital Outperform OutperformMaintainJul 8, 2026
Keybanc Overweight OverweightMaintainJun 22, 2026
Morgan Stanley Equal Weight OverweightDowngradeJun 17, 2026
Stifel Hold HoldMaintainJan 30, 2026
Show 26 more rating actions

Named analyst price targets

Upside is calculated against the persisted current price $206.78. FMP does not supply a rating on these named-analyst rows.

FirmAnalyst52W targetPrice when postedUpsideDate
UBSDavid Low$300$195.97 +45.1%Jul 21, 2026
RBC CapitalAnalyst unavailable$234$198.57 +13.2%Jul 16, 2026
Mizuho SecuritiesAnalyst unavailable$220$193.01 +6.4%Jul 15, 2026
JefferiesAnalyst unavailable$225$204.5 +8.8%Jul 10, 2026
RBC CapitalAnalyst unavailable$276$219.75 +33.5%Jul 8, 2026
Wells FargoAnalyst unavailable$225$219.75 +8.8%Jul 8, 2026
KeyBancAnalyst unavailable$266$188.63 +28.6%Jun 22, 2026
Morgan StanleyDavid Bailey$230$193.94 +11.2%Jun 17, 2026
Robert W. BairdAnalyst unavailable$225$203.87 +8.8%May 1, 2026
KeyBancAnalyst unavailable$290$219.85 +40.2%Apr 27, 2026
See 32 more

Track every rating change on RMD the moment it posts. Free to start.

Start free